

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Andrew A. YOUNG *et al.*

Appln. No.: 10/656,093

Filed: September 5, 2003

For: *Inotropic and Diuretic Effects of GLP-1 and GLP-1 Agonists*

Art Unit: 1651

Examiner: HEARD, Thomas Sweeney

Confirmation No.: 8873

Atty. Docket: 256/152 DIV

United States Patent and Trademark Office
Commissioner for Patents
Mail Stop AF
P.O. Box 1450
Alexandria, Virginia 22313-1450

TRANSMITTAL COVER SHEET

The following documents are being submitted in response to the Notice of Allowance and Fee(s) Due via EFS-Web at the United States Patent and Trademark Office on 13-Aug-08:

<u>Documents(s)</u>	<u>No. of Pages</u>
Part B – Fee(s) Transmittal	1
Notification of Loss of Small Entity Status	1
Transmittal Cover Sheet	1
Total Pages	3

Should any other fee become due or credit become payable during the pendency of these proceedings, the Commissioner is authorized to charge or credit the same to Deposit Account Number 010535.

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being electronically filed via EFS-Web at the United States Patent and Trademark Office, on August 13, 2008.


Kelly B. Solomon

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Andrew A. YOUNG *et al.*

Art Unit: 1651

Appln. No.: 10/656,093

Examiner: HEARD, Thomas
Sweeney

Filed: September 5, 2003

Confirmation No.: 8873

For: *Inotropic and Diuretic Effects of GLP-1 and GLP-1 Agonists* Atty. Docket: 256/152 DIV

NOTIFICATION OF LOSS OF SMALL ENTITY STATUS

Box Issue Fee:


Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR 1.27(g)(2), the undersigned hereby notifies the U.S. Patent and Trademark Office of loss of entitlement to small entity status. This notification is being submitted at the time of paying the earliest of an issue fee or a maintenance fee due after the date on which status as a small entity, as defined in 37 CFR 1.27(a), is no longer appropriate. This notification is signed by an appropriate party, as identified in 37 CFR 1.33(b).

The undersigned believes that the appropriate fee is enclosed or authorization has been given to charge the deposit account. However, in the event any additional fees are due or any amount is to be credited, the undersigned authorizes the Commissioner of Patents to debit or credit Deposit Account No. 010535.

Dated: 13-Aug-08

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.
By: 
Edward D. Grieff
Registration No. 38,898

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936